
illumicell AI is a Swiss-American techmed startup based at Harvard Pagliuca Life Lab that pioneers personalized health diagnostics through advanced imaging and AI technology. Originally designed for space exploration, their proprietary non-optic microscopy and AI algorithms analyze semen samples to unlock biomarkers related to male fertility, metabolic diseases, cancer risks, and longevity. Their portable lab scanner and real-time AI platform transform cellular data into actionable health insights, redefining fluid-based diagnostics at the point of care. illumicell AI has secured $2 million in pre-seed funding, installed its first U.S. system at Harvard, and is supported by leading experts in AI, healthcare, and biotech, positioning it strongly in the fertility and wellness diagnostics market.

illumicell AI is a Swiss-American techmed startup based at Harvard Pagliuca Life Lab that pioneers personalized health diagnostics through advanced imaging and AI technology. Originally designed for space exploration, their proprietary non-optic microscopy and AI algorithms analyze semen samples to unlock biomarkers related to male fertility, metabolic diseases, cancer risks, and longevity. Their portable lab scanner and real-time AI platform transform cellular data into actionable health insights, redefining fluid-based diagnostics at the point of care. illumicell AI has secured $2 million in pre-seed funding, installed its first U.S. system at Harvard, and is supported by leading experts in AI, healthcare, and biotech, positioning it strongly in the fertility and wellness diagnostics market.
What they do: Portable AI-powered non-optic microscopy platform for rapid, lab-grade fluid diagnostics (initial focus: semen/male fertility)
Headquarters: Allston, Massachusetts (Harvard Pagliuca Life Lab); offices in Zurich, Switzerland
Founding year: 2023
Funding: $2.0M announced pre-seed (Apr 2025); prior Techstars-related pre-seed (Oct 2023)
Team size (reported): ~15 employees
Point-of-care fluid diagnostics with emphasis on male fertility and wellness biomarkers.
2023
Biotechnology
Accelerator-related pre-seed round tied to Techstars
2000000
Announced $2.0M round with participation from KOFA Healthcare, Phoenix Investment Club, MedTech Syndicates and individual investors
“KOFA Healthcare; Phoenix Investment Club; MedTech Syndicates; Techstars; Brent Ahrens; Jeremy Teoh”